论文部分内容阅读
1942年,Keston首次报告某些甲癌转移灶摄取~(131)I,其后学者们发现,在去除正常甲状腺组织后,80～82％的甲癌转移灶有~(131)I摄取,且基本限于分化良好的乳头状癌、滤泡癌以及Hurthle细胞癌(常有明显滤泡成分),而髓样癌和巨大梭状细胞癌无摄取,为应用~(131)I诊断和治疗分化良好的甲癌转移灶奠定了理论基础。目前,~(131)I治疗甲癌已相当普遍,但对治疗中的某些问题尚有争论,故将有关资料综述如下。
In 1942 Keston first reported the uptake of ~(131)I in certain metastatic cancers. Later, the researchers found that after removing normal thyroid tissue, 80~82% of the metastatic tumors with ~(131)I uptake, and Basically limited to well-differentiated papillary, follicular, and Hurthle cell carcinomas (often with significant follicular components), whereas medullary carcinomas and giant spindle cell carcinomas have no uptake and are well-differentiated for the diagnosis and treatment of ~(131)I The metastasis of the nail cancer lays a theoretical foundation. At present, ~(131)I treatment of thyroid cancer is quite common, but there are still some disputes about treatment. Therefore, the relevant information is summarized as follows.